ArticleMicroorganisms2021
Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.
Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Advances in Ciprofloxacin Derivatives: Emerging Strategies to Combat Antimicrobial Resistance.Topics in current chemistry (Cham) · 2026Review
- Behavioral alterations in antibiotic-treated mice associated with gut microbiota dysbiosis: insights from 16S rRNA and metabolomics.Frontiers in neuroscience · 2025Article
- Resistance trend in bacteria isolated from corneal ulcers: A retrospective analysis from Pakistan.PloS one · 2025Article
- Combination of gallium citrate and levofloxacin induces a distinct metabolome profile and enhances growth inhibition of multidrug-resistantFrontiers in microbiology · 2024Article
- Metabolomics meets systems immunology.EMBO reports · 2023Review
- Comprehensive Two-Dimensional Gas Chromatography as a Bioanalytical Platform for Drug Discovery and Analysis.Pharmaceutics · 2023Review
- Alanine-mediated P cycle boosting enhances the killing efficiency of kasugamycin on antibiotic-resistantFrontiers in microbiology · 2023Article
- The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Frontiers in public health · 2022Review
- Enhanced Biosynthesis of Fatty Acids Contributes to Ciprofloxacin Resistance inFrontiers in microbiology · 2022Article
- Antibacterial Activity of the Essential Oil FromFrontiers in microbiology · 2022Article
- Multifunctional Gelatin/Chitosan Electrospun Wound Dressing Dopped withPharmaceutics · 2021Article
- Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the interest of developing more effective and safer anti-tuberculosis drugs, we used a GCxGC-TOF-MS metabolomics research approach to investigate and compare the metabolic profiles of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.